CClinicalTrials.gg
CompletedNCT00972088Updated Jun 24, 2013Results posted

Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease

An interventional study of capsule endoscopy in Inflammatory Bowel Disease, Perianal Fistula and Perianal Abscess, sponsored by Bikkur Holim Hospital. Completed at 3 sites in Israel. Open to participants aged 10 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-06-24.

Sponsored by Bikkur Holim Hospital · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
10 Years to 80 Years
Sex
All
01

Study summary

To show that prevalence of inflammation of the small bowel in patients with anorectal disease is under-diagnosed based on colonoscopy ileoscopy alone.

Read the detailed description

IBD of the small bowel is associated with perianal disease such as ano-rectal abscesses and fistulas. Colonoscopy with ileoscopy and small bowel series are relied upon to document the presence of Crohn's disease of the small bowel. We suspect that the prevalence of inflammatory small bowel disease is underestimated.

In my practice I have cases that had negative colonoscopy ileoscopy and positive findings at capsule endoscopy. These patients are receiving therapy for Crohn's disease. It is important to prove that the prevalence is higher.

Capsule Endoscopy (CE) is the "first line tool" diagnostic procedure for the examination of the small bowel. It is performed today in more than 2,900 GI clinics in hospitals, outpatient departments and physicians' offices all over the world using the PillCam® Platform. Over 500,000 CE procedures with the Given PillCam SB have been completed to date.

02

Conditions studied

  • Inflammatory Bowel Disease
  • Perianal Fistula
  • Perianal Abscess

Keywords

  • inflammation of the small bowel
03

In context

Intestinal Diseases

963 studies on the registry are indexed under Intestinal Diseases; 174 are open to participants now.

This study's enrollment of 26 is below the median of 70 across 552 interventional studies indexed under Intestinal Diseases.

Browse Intestinal Diseases studies →

Lead sponsor

Bikkur Holim Hospital is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients between the ages of 10 - 80
  • Patients with anorectal abscess of anorectal fistula
  • Patient is male or female
  • Within three months prior to enrollment, patient has normal test results for at least one of the following tests:

    1. Colonoscopy with Ileoscopy, and/or
    2. Colonoscopy with small bowel series, and/or
    3. Colonoscopy with CT enterography
  • Within three months prior to enrollment patient has the following lab tests: Blood count, sedimentation rate, CRP. IBD serology is optional.
  • Sign informed consent

Exclusion criteria

Exclusion Criteria:

  • Can not sign informed consent
  • Contraindications to colonoscopy ileoscopy or capsule endoscopy
  • History of established IBD
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Other
    capsule endoscopy

    patients eligible according to inclusion criteria who underwent a capsule endoscopy

    Device: capsule endoscopy

Interventions

  • Devicecapsule endoscopy

    The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.

06

What researchers measure

Primary outcomes

  1. Prevalence of Inflammation as Diagnosed by Capsule Endoscopy

    The capsule endoscopy findings were carefully examined by specialists in the field. findings such as erosions, edema, erythema and ulceration in significant areas of the intestine led to the clinical diagnosis of crohn's disease. all together 6 patients were diagnosed as suffering from crohn's disease.

    Time frame: up to 7 days

07

Results

Posted Jun 24, 2013

Participant flow

from 2009 until june 2011 26 patients were enrolled from gastroenterology clinics

Participant flow — Overall Study
Milestonea Single Arm Group, Patients With Ano Rectal Disease
Started26
Completed26
Not completed0

Outcome measures

PrimaryPrevalence of Inflammation as Diagnosed by Capsule Endoscopy

The capsule endoscopy findings were carefully examined by specialists in the field. findings such as erosions, edema, erythema and ulceration in significant areas of the intestine led to the clinical diagnosis of crohn's disease. all together 6 patients were diagnosed as suffering from crohn's disease.

Time frame:
up to 7 days
Reported as:
Number · participants
Prevalence of Inflammation as Diagnosed by Capsule Endoscopy
participantsAnorectal Disease, Negative Work up for Crohns Disease
Prevalence of Inflammation as Diagnosed by Capsule Endoscopy6

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anorectal Disease, Negative Work up for Crohns Disease—0/26 (0%)0/26 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Anorectal Disease, Negative Work up for Crohns Disease
<=18 years0
Between 18 and 65 years26
>=65 years0
Age Continuous
Age Continuous(years)Anorectal Disease, Negative Work up for Crohns Disease
Mean34.3 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Anorectal Disease, Negative Work up for Crohns Disease
Female9
Male17
Region of Enrollment
Region of Enrollment(participants)Anorectal Disease, Negative Work up for Crohns Disease
Israel26
08

Study locations

3 sites
  • Assaf Harofeh Medical Center
    Tel Aviv, Zrifin 70300, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Bikur Cholim Hospital
    Jerusalem, 91004, Israel
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00972088
Lead sponsor
Bikkur Holim Hospital
Responsible party
Sam Adler (Prof. Samuel N. Adler, MD, Bikkur Holim Hospital) — Principal investigator
First posted
Sep 4, 2009
Start date
Aug 2008
Primary completion
Jun 2011
Completion
Jun 2011
Results posted
Jun 24, 2013
Last update
Jun 24, 2013

Study contacts

Samuel Adler, Prof.
principal investigator · Bikur Cholim Hospital, Jerusalem

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion